The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG)

COVID-19 和癌症联盟：NCI 对 P30 癌症中心支持补助金 (CCSG) 的行政补充

基本信息

批准号：
10332040
负责人：
JENNIFER A PIETENPOL
金额：
$ 60万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10332040
关键词：
2019-nCoV Acute Administrative Supplement Advocate Affect Age-Years Antineoplastic Agents Automobile Driving Blood Transfusion COVID-19 COVID-19 morbidity COVID-19 patient Canada Cancer Center Support Grant Cancer Patient Case Study Categories Cessation of life Chronic Obstructive Airway Disease Colorectal Cancer Community Networks Community Practice Comprehensive Cancer Center Consultations Data Analyses Data Collection Databases Disease Goals Health Professional Healthcare Systems Image Immunocompromised Host Incidence Inflammatory Bowel Diseases Infusion procedures Institution Knowledge Malignant Neoplasms Malignant neoplasm of lung Marrow Mexico NCI-Designated Cancer Center Nature Participant Patients Pharmaceutical Preparations Provider Publishing Research Risk Site Social Work Steroids Supportive care Toxic effect Translational Research Venous blood sampling Virus Visit Work arm cancer cell cancer therapy comorbidity data cleaning data dissemination data registry data resource emerging pathogen high risk mortality novel virus pandemic disease prospective quality assurance ranpirnase social media viral transmission

项目摘要

Project Summary COVID-19, the disease caused by the SARS-coV-2 virus, has now affected nearly 100 million people globally, with nearly 2 million deaths. Patients with cancer have a unique risk profile in this pandemic. Many patients, especially those actively on treatment, have high levels of contact with the health care system. This can include provider visits, phlebotomy, imaging, social work and financial consultations, and infusion room visits for anti-cancer therapy and supportive care such as blood transfusions. Despite heroic efforts to reduce viral transmission in these shared spaces, patients are at an increased risk for COVID-19 exposure. Additionally, most cancer patients are immunocompromised through the marrow toxic effects of anti-cancer drugs, supportive medications such as steroids, and/or the cancer itself; and over 60 years of age, putting them in the highest-risk category for COVID-19-related morbidity and mortality. Finally, incidences of important comorbidities can be considerably elevated in several cancers, such as chronic obstructive pulmonary disease in lung cancer or inflammatory bowel disease in colorectal cancer, further exacerbating their vulnerability to this novel pathogen. Given an acute lack of knowledge and concern for extreme vulnerability, the COVID-19 and Cancer Consortium (CCC19) was formed in March 2020 to understand how the novel virus affects cancer patients. While this national effort began organically, primarily through social media, membership has quickly grown to over 450 healthcare professionals and patient advocates representing over 125 institutions and organizations in the US, Canada, and Mexico. Included in this membership are the majority of the NCI-designated Comprehensive Cancer Centers, NCI-Designated Cancer Centers and large networks of community practices, many of which are NCORP sites. The driving goal of the consortium is to collect prospective, granular, uniformly organized information to help generate hypotheses for translational science, and to arm treating providers with the most complete data resource as rapidly as possible on cancer patients infected with COVID-19. As of January 2021, CCC19 has collected over 8000 case reports of high analytical quality, and has published initial results in The Lancet, Cancer Discovery, Cancer Cell, and Nature Cancer. As the Research Coordinating Center for the consortium, we establish and propagate best practices for governance, data collection, and data dissemination. We host the main data registry, conduct data cleaning, quality assurance, and central data analysis, and will work with participant institutions who choose to set up mirrored local databases.

项目概要由 SARS-coV-2 病毒引起的疾病 COVID-19 现已影响近 1 亿人全球有近 200 万人死亡。癌症患者在这方面具有独特的风险特征大流行。许多患者，尤其是那些积极接受治疗的患者，与患者有大量接触。医疗保健系统。这可以包括提供者访问、静脉切开术、成像、社会工作和财务咨询、输液室就诊以进行抗癌治疗和支持性护理，例如如输血。尽管为减少这些共享空间中的病毒传播做出了英勇的努力，患者接触 COVID-19 的风险增加。此外，大多数癌症患者由于抗癌药物的骨髓毒性作用而导致免疫功能低下，支持类固醇等药物和/或癌症本身；并且超过60岁，将他们放入与 COVID-19 相关的发病率和死亡率最高风险类别。最后，发生率在多种癌症中，重要的合并症可能会显着增加，例如慢性癌症肺癌中的阻塞性肺病或结直肠癌中的炎症性肠病，进一步加剧了他们对这种新型病原体的脆弱性。鉴于严重缺乏知识和对极端脆弱性的担忧，COVID-19 和癌症联盟 (CCC19) 于 2020 年 3 月成立，旨在了解新型病毒如何影响癌症患者。虽然这项国家努力是有机地开始的，主要是通过社会媒体、会员已迅速增加到超过 450 名医疗保健专业人员和患者代表美国、加拿大和墨西哥超过 125 个机构和组织的倡导者。该成员中包括大多数 NCI 指定的综合癌症患者中心、NCI 指定的癌症中心和大型社区实践网络，其中许多这些是 NCORP 站点。该联盟的驱动目标是收集前瞻性的、细粒度的、统一组织的信息有助于产生转化科学的假设，并武装尽快为癌症患者提供最完整的数据资源进行治疗感染了 COVID-19。截至2021年1月，CCC19已收集了8000多份病例报告分析质量高，并已在《柳叶刀》、《癌症发现》、《癌症》上发表初步结果细胞和自然癌症。作为该联盟的研究协调中心，我们建立和传播最好的治理、数据收集和数据传播的实践。我们托管主要数据注册表，进行数据清理、质量保证和中央数据分析，并将与参与者合作选择建立镜像本地数据库的机构。